Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0004153 (atherosclerosis)
 77,401 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Ten out-patients with primary Type IIa hyperlipoproteinemia and a further 10 with Types IIb, IV, and V were administered with DL-alpha-methyl-thyroxine ethyl ester (etiroxate) (20 mg twice daily) for an average of 308 days. The aim of the study was to determine the effects of the drug on the cholesterol and triglyceride levels, tolerance and side-effects, particularly in coronary patients. The T4 values rose in all but one patient and fell again when the drug was discontinued. In Type IIa patients cholesterol fell by an average of 75.5 mg/100 ml (20.6%) as compared with the period before treatment and normal triglyceride levels dropped by 17 mg/100 ml (12.6%). In Type IIb, IV and V patients cholesterol levels decreased by 69.1 mg/100 ml (21%) during treatment. Serum triglycerides, which in some patients were extremely high before treatment were only slightly affected, falling by an average of 165.3 mg/100 ml (22.8%). For the whole group of patients the fall in cholesterol during treatment was highly significant in comparison with the period before and after therapy, whereas the changes in the triglycerides were not significant. Only one patient had an increase in the frequency of angina pectoris attacks; another showed temporary restlessness and slies, were not observed. Red and white cell counts, differential blood count, thrombocytes, the transaminases SGOT, SGPT, alkaline phosphatase, bilirubin, urinalysis and erythrocyte sedimentation rate did not change during treatment. There was no lasting increase in pulse rate in any patient and no significant changes in systolic-diastolic blood pressure. ECG showed no rhythm disorders nor any other changes which were not present before treatment was initiated.
Atherosclerosis
PMID:Reduction of serum lipids by means of etiroxate (Liponorm). 121 78

Breddin thrombagglutination test is followed up in patients with hypercoagulation states--atherosclerosis, atherosclerotic myocardiodysthrophia, angina pectoris gravis and acute myocardial infarction and hypocoagulation states--esential and symptomatic thrombopenia. TAT is positive in 88% of the patients with atherosclerosis and in patients with angina pectoris gravis and myocardial infarction TAT is Vth stage in 100%. TAT is zero stage in 91% in patients with thrombopenia and only in 9%-I stage. The term "zero stage" is introduced.
 ...
PMID:[Thrombagglutination test (TAT) in hyper- and hypocoagulation]. 122 97

Coronary- and LV-angiography in coronary heart disease are indicated I) to clarify whether or not surgery is required (e.g. aorto-coronary-bypass operation, aneurysmectomy) in 1) drug resistent angina pectoris, 2) myocardial aneurysms (or the suspicion of), 3) VSD following myocardial infarction and/or 4) as preoperative investigations in mitral regurgitation or 5) other valve lesions. II) These investigations are furthermore indicated in the under-50-yr.-old considering their prognosis and diagnosis 1) following myocardial infarction 2) to clarify a pathological exercise test with or without angina pectoris 3) in the differential diagnosis of myocardial diseases and 4) occasionally in patients with a number of risk factors or exposed to particular occupational hazards or from families with a high incidence of early deaths from heart disease. Coronary- and LV-angiography are contraindicated in 1) generalized stenosing atherosclerosis, 2) acute myocardial infarction, 3) failure from other organ-systems (e.g. kidney), 4) drug resistent endogenous risk factors and/or relevant obesity, 5) biological age over 60-65.6) continued nicotine dependence. In many cases the specific diagnostic investigations will include the assessment of coronary flow at rest and during maximal drug induced coronary dilatation. This enables us to estimate the coronary reserve and to diagnose coronary insufficiency in patients with normal coronary angiograms.- Instructive morphological and/or functional results illustrate this presentation.
 ...
PMID:[Indications for coronary arteriography and left ventriculography in coronary heart disease (author's transl)]. 125 Nov 19

Sixteen male patients with typical angina pectoris secondary to coronary atherosclerosis performed two daily standardized exercise tests during two consecutive days. Three hours before each exercise they received placebo or 400 mg practolol administered orally in double-blind fashion in order to complete a cross-over design. Practolol significantly prolonged the exercise duration by 30.6% and delayed the appearance time of ischaemic electrocardiographic changes by 67.7%. Maximal heart rate, systolic pressure, and pressure-rate product were also reduced after medication. In order to investigate further the effects of this beta blocking agent, myocardial function and metabolism at rest and during supine exercise were assessed in 12 male patients with coronary artery disease before and after practolol 30 mg, iv. At rest, practolol produced a decrease in tension-time index (18%), cardiac index (17%), heart rate (10%), and stroke index (7%). A significant reduction was also observed in resting stroke work index (14%) and systolic and mean aortic pressure (6%). Left ventricular end-diastolic pressure remained unchanged. During supine exercise, only time-tension index (12%), heart rate (12%), and cardiac index (10%) were significantly reduced after the beta blocking agent. Practolol did not significantly change the arterial glucose, lactate, inorganic phosphate, potassium, calcium, magnesium, pH, PCO2, or PO2. The beta blocking agent did not modify the myocardial extraction of any of these substrates at rest or during exercise. In the dosage used in both studies, practolol significantly improved the exercise tolerance and reduced the ischaemic manifestations. The efficacy of practolol in angina pectoris may result mostly from its ability to decrease heart rate and systolic pressure during exercise.
 ...
PMID:Effects of practolol on exercise tolerance and cardiac haemodynamics and metabolism in patients with coronary artery disease. 125 93

Acute myocardial infarction in systemic lupus erythematosus may be due to an atheromatous or arteritic process. Confirmation of the latter etiology has previously been made only at postmortem examination. A 45-year-old white woman with known systemic lupus erythematosus developed anginal pain and multiple episodes of acute myocardial infarction. During this period, there was serologic but no other clinical evidence of active systemic lupus erythematosus. Serial coronary angiographic studies were strongly suggestive of an arteritic process based upon (1) a saccular aneurysm with no obstructive lesions in a coronary artery supplying an area of recent transmural myocardial infarction and (2) the development of significant obstructive lesions in a previously normal coronary artery over a period of 18 days. This case illustrates the difficulties in distinguishing between atherosclerosis and arteritis using a single coronary angiographic study. The distinction is significant because of the different therapeutic interventions required.
 ...
PMID:Coronary arteritis in systemic lupus erythematosus. 126 86

Calcium-antagonist drugs are therapeutic agents of first choice in patients with coronary artery disease. We have reviewed a number of clinical trials in which the safety and efficacy of calcium blockers have been tested and discuss the established clinical effects of these compounds, which range from relief of angina and improved quality of life (both in patients with ischemia due to reduction in coronary flow and in patients with ischemia due to increased O2 demand) to a favorable effect on the course of coronary atherosclerosis and, finally, (at least for some of these agents) to an improvement in prognosis.
 ...
PMID:Clinical evaluation of calcium-antagonist drugs. 128 60

Long-term (5-15-year) prospective surveys of 171 angina patients have yielded clinical, coronarographic, and bicycle ergometric criteria for predicting the favourable course of the disease. A prolonged (at least 3 years) clinical anginal remission was observed in 43 (25.1%) patients. The patients had typical features: a short (less than 6-9 months) history of classical angina, the age at the onset of CHD under 50 years; high performance during bicycle ergometric test, lack of angina after sustained so-called "accomplished" myocardial infarction. The coronarograms of patients with a long-term anginal remission most frequently displayed severe stenosis or occlusion of "unsafe" site of a large coronary artery. The duration of remission was less than 10 years if atherosclerosis also affected the remaining coronary arteries. That of remission was more than 10-15 years, if the remaining coronary arteries proved completely intact.
 ...
PMID:[Clinical and functional characteristics of patients with ischemic heart disease in long-term remission of angina pectoris]. 128 6

Randomized controlled trials along with 'within group' studies of patients with symptomatic coronary artery disease suggest that dietary and other lifestyle changes can halt progression of coronary atherosclerosis, induce regression of pre-existing severe lesions, and reduce the severity or frequency of angina. Varying combinations have been tested, including restriction of dietary total, saturated and polyunsaturated fat using lean meat or vegetarian diets, fish oil supplements, smoking cessation, stress management, and exercise training. The relative importance of each of these remains unclear. In patients with recent myocardial infarction high fish diets appeared effective in reducing both ischaemic heart deaths and total death rates over two years, whereas modest changes in dietary saturated fats or fibre had no influence on outcome. These results suggest that a far more active dietary approach is needed for patients with symptomatic coronary disease. Further research is required into the possible complementary role of dietary measures and drug treatment for reversing the disease process and improving outcome, using new techniques for achieving behavioural change.
 ...
PMID:Strategies and difficulties in dietary intervention in myocardial infarction patients. 131 46

As many as 103 men who suffered myocardial infarction were examined for the clinical and functional manifestations of cerebral circulatory disorders as well as for the coronary heart disease at rest and during bicycle ergometry. The majority of the patients with postinfarction cardiosclerosis were found to have changes in the rheoencephalograms, augmenting with physical exercise. Those changes were most pronounced in patients with the clinical manifestations of atherosclerosis of cerebral vessels and in the presence of angina pectoris. The simultaneous recording of the rheoencephalogram and electrocardiogram during bicycle ergometry can be used for an all-round estimation of the reserves of cerebral and coronary circulation in patients suffering from coronary heart disease and elaboration of rehabilitation measures.
 ...
PMID:[Rheoencephalography as an indicator of disorders of cerebral circulation in patients after myocardial infarction]. 132 77

Elevated levels of lipoprotein(a) [Lp(a)] have been associated with an increased risk of ischemic heart disease (IHD), and higher levels of Lp(a) are associated with lesions of significantly greater severity. We have examined Lp(a), total cholesterol (TC) and high density lipoprotein-cholesterol (HDL-C) levels in patients with IHD including those with normal coronary arteries with vasospastic angina. The study population consisted of 206 patients (166 males and 40 females) who underwent diagnostic coronary angiography for known IHD. Twenty-eight patients had effort angina, 36 rest angina, 8 unstable angina and 134 old myocardial infarction. IHD patients were categorized as zero vessel disease (0VD), single vessel disease (SVD) and multi-vessel disease (MVD). To investigate the relationship between atherosclerosis and IHD, these patients were further divided into 3 groups based on angiographic findings. Eighteen patients had entirely normal coronary arteries (normal group), 24 discretely diseased coronary arteries (discrete group) and 80 diffusely diseased coronaries (diffuse group). The results were compared with those obtained from 50 healthy individuals. Lp(a) levels for IHD patients (12.4 mg/dl) were significantly higher than those of controls (7.1 mg/dl, p < 0.05). However, there were no statistical differences between 0VD (13.1 mg/dl) and MVD (12.8 mg/dl). Similarly, no statistical differences of Lp(a) values were found among the normal group (13.3 mg/dl), discrete group (12.0 mg/dl) and diffuse group (12.9 mg/dl). Mean levels of HDL-C in 0VD (51.3 +/- 13.5 mg/dl) were significantly higher than those of SVD (42.9 +/- 11.5 mg/dl, p < 0.05). However, no significant differences were observed between controls (59.5 +/- 15.3 mg/dl) and 0VD (51.3 +/- 13.5 mg/dl).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Importance of lipoprotein(a) in patients with ischemic heart disease]. 133 90


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>